CN116096713A - 化合物的固体形式 - Google Patents

化合物的固体形式 Download PDF

Info

Publication number
CN116096713A
CN116096713A CN202180058118.8A CN202180058118A CN116096713A CN 116096713 A CN116096713 A CN 116096713A CN 202180058118 A CN202180058118 A CN 202180058118A CN 116096713 A CN116096713 A CN 116096713A
Authority
CN
China
Prior art keywords
solid form
cancer
xrpd
peaks
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180058118.8A
Other languages
English (en)
Inventor
王在琪
高晶
桑迎霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yingshi Biotechnology Nanjing Co ltd
Original Assignee
Yingshi Biotechnology Nanjing Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yingshi Biotechnology Nanjing Co ltd filed Critical Yingshi Biotechnology Nanjing Co ltd
Publication of CN116096713A publication Critical patent/CN116096713A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

提供式(I)化合物或其盐、或其溶剂化物、或其盐的溶剂物、或其混合物的固体形式。

Description

PCT国内申请，说明书已公开。

Claims (47)

  1. PCT国内申请，权利要求书已公开。
CN202180058118.8A 2020-08-03 2021-08-02 化合物的固体形式 Pending CN116096713A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020107687301 2020-08-03
CN202010768730 2020-08-03
CN202010837005 2020-08-19
CN2020108370055 2020-08-19
PCT/CN2021/110069 WO2022028367A1 (zh) 2020-08-03 2021-08-02 化合物的固体形式

Publications (1)

Publication Number Publication Date
CN116096713A true CN116096713A (zh) 2023-05-09

Family

ID=80119956

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180058118.8A Pending CN116096713A (zh) 2020-08-03 2021-08-02 化合物的固体形式

Country Status (13)

Country Link
US (2) US20230278985A1 (zh)
EP (1) EP4190774A4 (zh)
JP (1) JP2023536491A (zh)
KR (1) KR20230048089A (zh)
CN (1) CN116096713A (zh)
AU (1) AU2021323235A1 (zh)
BR (1) BR112023001962A2 (zh)
CA (1) CA3188244A1 (zh)
CL (1) CL2023000313A1 (zh)
MX (1) MX2023001418A (zh)
PE (1) PE20231303A1 (zh)
TW (1) TW202206425A (zh)
WO (1) WO2022028367A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023160614A1 (zh) * 2022-02-28 2023-08-31 微境生物医药科技(上海)有限公司 作为fak抑制剂的化合物及其用途
WO2023246869A1 (zh) 2022-06-24 2023-12-28 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074210A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
US20220340540A1 (en) * 2019-03-28 2022-10-27 Amplia Therapeutics Limited A salt and crystal form of a fak inhibitor
WO2020202005A1 (en) * 2019-04-02 2020-10-08 Inxmed (Shanghai) Co., Ltd. Combination of a fak kinase inhibitor and an agent targeting t-cell co-stimulatory receptors
JP2023503897A (ja) * 2019-11-18 2023-02-01 ▲應▼世生物科技（南京）有限公司 Ｎｒａｓ変異を有する腫瘍を治療するための医薬品の調製におけるｆａｋ阻害剤の使用
CN114728005A (zh) * 2019-11-28 2022-07-08 应世生物科技(南京)有限公司 Bi853520在癌症治疗中的用途
US20230103007A1 (en) * 2020-01-31 2023-03-30 Verastem, Inc. Combination therapy for treating abnormal cell growth
MX2022009612A (es) * 2020-02-05 2022-09-19 Inxmed Nanjing Co Ltd Combinacion de bi853520 con farmacos quimioterapeuticos.

Also Published As

Publication number Publication date
TW202206425A (zh) 2022-02-16
EP4190774A1 (en) 2023-06-07
JP2023536491A (ja) 2023-08-25
US20230278985A1 (en) 2023-09-07
BR112023001962A2 (pt) 2023-04-11
CL2023000313A1 (es) 2023-07-28
KR20230048089A (ko) 2023-04-10
US20240051942A1 (en) 2024-02-15
CA3188244A1 (en) 2022-02-10
PE20231303A1 (es) 2023-08-24
EP4190774A4 (en) 2024-01-17
AU2021323235A1 (en) 2023-03-02
WO2022028367A1 (zh) 2022-02-10
MX2023001418A (es) 2023-04-10

Similar Documents

Publication Publication Date Title
RU2497820C2 (ru) Кристаллические формы и две сольватные формы солей молочной кислоты 4-амино-5-фтор-3-[5-(4-метилпиперазин-1-ил)-1 - н-бензимидазол-2-ил]хинолин-2(1н)она
US20240051942A1 (en) Solid form of compound
CN108884072A (zh) Egfr抑制剂游离碱或其酸式盐的多晶型、其制备方法和应用
WO2011163430A9 (en) Polymorphs of osi-906
EP3842434A1 (en) Crystal polymorph of 8-bromo-2-(1-methylpiperidin-4-ylamino)-4-(4-phenoxyphenylamino)pyrido[4,3-d]pyrimidin-5(6h)-one hydrochloride and method for preparing same
KR20170032330A (ko) Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
EP3430004B1 (en) Solid state forms of nilotinib salts
JP7351061B2 (ja) 縮合環ピリミジン系化合物の塩、結晶形並びにその製造方法と使用
CN114671879A (zh) 一种嘧啶并五元氮杂环类衍生物的晶型及其制备方法
CN116768856A (zh) 一种取代的氨基六元氮杂环类化合物的盐及其晶型、制备方法和应用
US20220332706A1 (en) Crystalline forms of a jak2 inhibitor
WO2013181251A9 (en) Crizotinib hydrochloride salt in crystalline
RU2684278C1 (ru) Фумарат пиридиламина и его кристаллы
CN110117272B (zh) 细胞周期蛋白依赖性激酶抑制剂的盐及其晶型
US20240116925A1 (en) Salt of nitrogen-containing fused heterocyclic compound or crystal form thereof, and preparation method therefor, pharmaceutical composition thereof, and use thereof
KR20200006078A (ko) 화합물의 염 및 그것의 결정 형태
WO2023242809A1 (en) Crystalline forms of 4-[(5-chloropyridin-2-yl)methoxy]-1-[3-(propan-2-yl)-1h,2h,3h,4h,5h-[1,4]diazepino[1,7-a]indol-9-yl]-1,2-dihydropyridin-2-one and salts thereof, method of preparation, and uses thereof
CN117209500A (zh) Shp2抑制剂、其晶型及其制备方法与用途
TW202415661A (zh) ４－〔（５－氯吡啶－２－基）甲氧基〕－１－〔３－（丙－２－基）－１Ｈ，２Ｈ，３Ｈ，４Ｈ，５Ｈ－〔１，４〕二氮呯并〔１，７－ａ〕吲哚－９－基〕－１，２－二氫吡啶－２－酮之晶形及其鹽，製備方法，及其用途
CN114075135A (zh) 含邻氨基吡啶炔基的化合物的盐及其制备方法和应用
CN117247382A (zh) 吡啶并嘧啶酮化合物的晶型
CN116685588A (zh) 吡啶并吡咯类化合物的晶型、制备方法及其应用
CN111848580A (zh) 含1,2,4-三嗪-3,5-二酮的喹啉类化合物的晶型及其制备方法和应用
WO2016101912A1 (zh) 一种表皮生长因子受体激酶抑制剂的盐的晶型及其制备方法
CN107629048A (zh) 一种酪氨酸激酶抑制剂的苹果酸盐的结晶形式及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination